Home / News / Pearce IP Blog
Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the...
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA...
The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news...
In the quest for a more sustainable future, not least of all in response to the pressing issues of climate change and...
In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make...
Introduction Pharmacia LLC and Pfizer Australia Pty Ltd (together, Pharmacia) have partially succeeded at first...
Introduction The decision of the High Court in H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4 (Lundbeck) last week...
On 18 March 2022, the Full Court gave highly awaited judgments in two cases[1] concerning the validity of patent term...
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs)...
Shortly before Christmas, the judgment handed down by Justice Burley on 18 November 2021 on a second preliminary...
Newly appointed Justice Rofe delivered an early Christmas gift for generic and biosimilar companies in Australia in...
In early November Pearce IP reported on a number of Federal Court decisions which appear to indicate flaws in the...
In the last sitting of Parliament for 2021, the House of Representatives delivered the long-awaited Zimmerman Report,...
The speed of getting a case to trial is a key metric of any litigation system. Pharmaceutical patent litigation often...
In the last year, two significant Federal Court decisions, reported here and here have exposed key flaws in the...